GTC is proud to present its 12th Vaccines Research & Development: All Things Considered Conference, to be held in Boston, MA on July 9-11, 2014. This conference continues a tradition of presenting valuable updates and exposure to all aspects of vaccine development, including research, product design considerations / specifications, manufacturing, regulations, investment, and policy, in a comfortable, interactive and friendly setting. It brings together the leaders in vaccinology from industry, academia, and the government for practical discussions of the future of our discipline.

Development of new vaccines truly requires a consideration of many things. We examine vaccine development from basic research to marketing. We bring together the people who make the discoveries, make the decisions, fund the work and license the vaccines and foster their interaction with the attendees to share their perspectives of the vaccine industry. The latest information on the new malaria, HIV, tumor, and therapeutic vaccines, DNA vaccines, RNA vaccines, adjuvants, mucosal and other delivery mechanisms will be presented, as will updates on governmental priorities, funding and partnership opportunities.

http://www.gtcbio.com/conference/vaccines-research-and-development-overview

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets and therapeutics provide new opportunities for the prevention and treatment of several major disease systems. The 5th Cancer Targets & Therapeutics Conference, taking place on July 7-8, 2014 in Boston, MA will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials, working to identify and exploit advances in the field in order to deliver products with a meaningful clinical impact. Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer.

2014 Session Topics:
I. Bridging Genomics & Proteomics in Cancer
II. Cancer Biomarkers in Discovery & Clinical Trials
III. Emerging Cancer Targets & Therapeutic Strategies
- Kinse Inhibitors
- Epigenetic Regulators
- Metabolic Pathways
- Cancer Stem Cells
IV. Progress in Cancer Immunotherapy
V. Combination Strategies in Immuno-Oncology
VI. Clinical Drug Development

This conference is part of our larger Novel Cancer Therapeutics Summit 2014, which includes one additional parallel conference:
Novel Cancer Therapeutics Summit 2014:
2nd Oncology Partnering & Deal-Making
4th Cancer Targets & Therapeutics

http://www.gtcbio.com/conference/cancer-targets-overview

Venue: Holiday Inn Regents Park Hotel, London, United Kingdom

SMi are proud to present their 14th Annual Pain Therapeutics Conference taking place in Central London on Monday 19th and Tuesday 20th May 2014.

This event will focus on the advances and challenges of pre-clinical and clinical aspects of pain drug development.

The agenda will give delegates an in-depth analysis on the strategies from bench to bedside to enhance drug development.

New mechanisms will also play an important role when evaluating novel targets with alternative approaches to animal ‘pain’ models and personalised medicines as an exploratory area.

The translation gap between animal data and humans is significant, enabling delegates to review proof of concept for pain modelling in humans.

New sessions for 2014 will include:

• Advances in recent neuropathic pain developments will be studied, in addition to assessing new therapeutic strategies for pain reduction

http://www.smi-online.co.uk/pharmaceuticals/uk/conference/pain-therapeutics

Venue: Holiday Inn Regents Park Hotel, London, United Kingdom

Antibody Drug Conjugates (ADCs) offer the promise and potential of delivering powerful tumour-killing activity with the advantage of reduced side effects for cancer patients. While one of the biggest challenges in manufacturing these powerful ADCs is controlling all the components that go into the final conjugation step, researchers do believe that further improvements and research in ADC design can and are resulting in a new generation of agents

Following on from the success of past events,SMI are proud to present 3rd annual Antibody Drug Conjugates Summit, 19th-20th May 2014, London. Focusing on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, this important and timely meeting will bring together key industry experts from academia and large and small pharma and biotech companies.

Join us and hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.

Key Topics include:

• Exploring nano-delivery systems
• Advancing preclinical development to accelerate ADCs into the clinic
• Refining next generation ADCs
• Learn how to overcome manufacturing challenges

http://www.smi-online.co.uk/pharmaceuticals/uk/conference/adc-summit

Adaptive Designs in Clinical Trials

24^th – 25^th March 2014

Holiday Inn Regents Park, London, UK

SMi is proud to present its 8th annual Adaptive Designs in Clinical Trials conference, held in central London on the 24 & 25 March 2014.

Hear through case studies how all sizes of pharmaceutical companies have successfully implemented trials incorporating adaptive designs. This conference is the only in Europe that focuses on adaptive designs specifically, providing delegates with updates on recent developments in enrichment design, dose response modelling, computer simulation, internal and external regulatory expectations and new data on evaluating adaptive dose ranging studies.

Adaptive Designs in Clinical Trials 2014 aims to show you how you can quickly and accurately implement an adaptive design clinical trial for your drug development - from initial processes in managing trials to choosing the right time to implement change

WHY ATTEND THIS EVENT:

• Learn from Michael Krams how to create an environment where adaptive designs can become the norm

• The only conference in Europe to focus specifically on adaptive designs in clinical trials

• Benefit from the first-hand experiences of speakers whose organizations have recently made breakthroughs in adaptive designs

• Hear from Vladimir Anisimov the very latest on predicative analytical techniques for increasing efficiency of drug development

• Discover at our post conference workshop how FACT software that supports the ever increasing complexity of adaptive clinical trials works, hosted by Tom Parke of Tessella

KEY SPEAKERS INCLUDE:

• Michael Krams, MD, Global Head, Quantitative Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson

• Vladimir Anisimov, Senior Strategic Biostatistics Director, Quintiles

• Roger Lewis, MD, PhD, Senior Medical Scientist, Berry Consultants

• Loïc Darchy, Head of Statistical Methodology Group, Sanofi R&D

• Lilla Di Scala, Senior Statistical Scientist, Roche

• Pantelis Vlachos, Principle Biostatistician, Strategic Consulting, Cytel Corporation

• Sue Todd, Professor of Medical Statistics, University of Reading

• Frank Fleisher, Principal Statistician, Boehringer-Ingelheim

• Christopher Jennison, Professor of Statistics, University of Bath

• Graeme Archer, Statistics Director, GlaxoSmithKline

PLUS TWO INTERACTIVE POST-CONFERENCE WORKSHOPS

Workshop A: Simulating Clinical Trials using the FACTS software package: Why simulate clinical trials, how to simulate clinical trials and the difference it will make. Wednesday 26th March 2014 | Holiday Inn Regents Park, London, UK |8.30am – 1.00pm. Workshop Leader: Tom Parke, Head of Clinical Trial, Solutions, Tessella Ltd

Workshop B: Identifying and Exploiting Opportunities for Efficiency in Clinical Trial Design: An Interactive Adaptive Design Workshop. Wednesday 26th March 2014 | Holiday Inn Regents Park, London, UK | 1.00pm - 5.00pm. Workshop Leader: Professor Roger J. Lewis, MD, PhD, Senior Medical Scientist, Berry Consultants

For more information on this conference visit http://www.smi-online.co.uk/2014adaptivedesign11.asp or contact Fateja Begum on +44 (0) 20 7827 6184 or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it